Aethlon Medical Inc (AEMD) concluded trading on Wednesday at a closing price of $1.45, with 5.1 million shares of worth about $7.4 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -77.34% during that period and on July 09, 2025 the price saw a gain of about 21.85%. Currently the company’s common shares owned by public are about 2.59M shares, out of which, 2.43M shares are available for trading.
Stock saw a price change of 22.88% in past 5 days and over the past one month there was a price change of -45.06%. Year-to-date (YTD), AEMD shares are showing a performance of -59.77% which decreased to -78.92% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.10 but also hit the highest price of $8.44 during that period. The average intraday trading volume for Aethlon Medical Inc shares is 108.93K. The stock is currently trading -6.69% below its 20-day simple moving average (SMA20), while that difference is down -40.75% for SMA50 and it goes to -58.43% lower than SMA200.
Aethlon Medical Inc (NASDAQ: AEMD) currently have 2.59M outstanding shares and institutions hold larger chunk of about 16.36% of that.
The stock has a current market capitalization of $3.75M and its 3Y-monthly beta is at 1.72. It has posted earnings per share of -$8.49 in the same period. It has Quick Ratio of 3.13 while making debt-to-equity ratio of 0.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AEMD, volatility over the week remained 14.70% while standing at 14.91% over the month.
Stock’s fiscal year EPS is expected to rise by 76.04% while it is estimated to increase by 70.08% in next year. EPS is likely to grow at an annualized rate of 60.97% for next 5-years, compared to annual growth of 43.53% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on July 07, 2025 offering a Neutral rating for the stock and assigned a target price of $1.50 to it.
